Vessel embolic material comprising hydrogel and therapy with the use thereof

• US 7,476,648 B1
• Filed: 10/26/2000
• Issued: 01/13/2009
• Est. Priority Date: 10/26/1999
• Status: Active Grant

• Current Assignee: Kaken Pharmaceutical Company Limited
• Original Assignee: Kaken Pharmaceutical Company Limited, Susumu Miyamoto, Yasuhiko Tabata
• Inventors: Tabata, Yasuhiko, Miyamoto, Susumu
• Primary Examiner(s): Kemmerer; Elizabeth C.
• Assistant Examiner(s): BORGEEST, CHRISTINA M
• Application Number:
  US10/111,483
• Time in Patent Office: 3,001 Days
• Field of Search: 514/2, 530/350
• US Class Current: 514/1.1
• CPC Class Codes: A61B 17/12022 Occluding by internal devices, e.g. balloons or releasable wires plugging an opening in the wall of an organ A61B17/0057; occluders for the cervical canal A61F6/146; vas deferens occluders A61F6/20
• CPC Class Codes: A61B 17/12113 within an aneurysm
• CPC Class Codes: A61B 17/12186 liquid materials adapted to be injected
• CPC Class Codes: A61B 17/1219 expandable in contact with liquids
• CPC Class Codes: A61L 2300/414 Growth factors
• CPC Class Codes: A61L 2300/418 Agents promoting blood coagulation, blood-clotting agents, embolising agents
• CPC Class Codes: A61L 2430/36 for embolization or occlusion, e.g. vaso-occlusive compositions or devices artificial blood vessels A61L27/507
• CPC Class Codes: A61L 31/145 Hydrogels or hydrocolloids
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/14 Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Abstract

According to the present invention, a vessel embolic material comprising a hydrogel containing a cell growth factor, which is applicable to embolic operations for various vascular disorders, excellent in high adaptability to a living body, can be easily handled, ensures the occlusion of the affected part and can maintain the occlusion for a long time, and a method of treatment using the same can be provided.

Claims

1. A method of treating an aneurysm comprising applying a cross-linked gelatin hydrogel containing bFGF to an affected blood vessel site wherein the aneurysm is located and wherein the cross-linked gelating hydrogel containing bFGF gradually releases bFGF resulting in occlusion of the lumen of the affected blood vessel site thereby treating the aneurysm and further wherein the aneurysm is an aneurysm in a form of a protrusion or a knob of size 1-20 mm.

2. The method of treating an aneurysm according to claim 1, wherein the cross-linked gelatin hydrogel is an alkali treated gelatin having an isoelectric point of 4.9 or an acid treated gelatin having an isoelectric point of 9.0.

3. The method of treating an aneurysm according to claim 1, wherein the cross-linked gelatin hydrogel is a material in which gelatin is cross-linked by glutaraldehyde or 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride.

4. The method of treating an aneurysm according to claim 1, wherein the cross-linked gelatin hydrogel is a material in which gelatin is cross-linked by a heat-treatment or irradiation of UV-rays.

5. The method of treating an aneurysm according to claim 1, wherein the hydrogel has a shape of rectangular, cylindrical, sheet, disc, sphere, or granular.

6. The method of treating an aneurysm according to claim 1, wherein a water content of the hydrogel is about 50 to 99 w/w %.

7. The method of treating an aneurysm according to claim 1, wherein the bFGF is contained in an amount of 0.1 to 1,000 μ

g in the hydrogel to be administered to the affected blood vessel or around the affected blood vessel site.